LGALS1 and cancer: Recent data have shown that head and neck cancer can have Gal1-driven resistance to immunotherapy, and that Gal1 inhibition with CRISPR/Cas9 or an antibody enhances anti-PD1 therapy, suggesting that a combination of Gal1 inhibitors and α-PD1/PDL1 immune checkpoint synergize for cancer treatment [114].